抗血管内皮生长因子药物治疗新生血管性老年性黄斑变性应答不良及无应答现象机制研究的进展被引量：10

Progress in the study of anti-vascular endothelial growth factor application for the treatment of neovascular age-related macular degeneration and the mechanism of poor and non-response

原文传递

导出

摘要抗血管内皮生长因子（VEGF）药物治疗新生血管（CNV）性老年性黄斑变性（nAMD）的效果根据其视力和黄斑中心凹视网膜形态改变等疗效评价指标可出现不同的应答反应,包括应答不良与无应答现象.nAMD疾病自身以及治疗药物相关的基因、CNV发生发展的相关因子和组织解剖结构、药物效率及药代动力学特性等是抗VEGF药物治疗nAMD出现应答不良与无应答现象的可能相关影响因素.应答不良与无应答现象的形成机制是抗VEGF药物治疗nAMD的关注热点,值得进一步深入探讨. According to the best corrected visual acuity and the morphological changes of the macular fovea,responses to the neovascular age-related macular degeneration （nAMD） who receive anti-vascular endothelial growth factor （VEGF） therapy show large variability,including poor and non-responders.Various factors will be reviewed to account for poor and non-response to anti-VEGF therapy,such as the related susceptibility genes,factors related with the development of choroidal neovascularization and morphologic parameters,pharmacokinetics and tachyphylaxis.The future research should focus on comprehensive assessment of factors affecting the efficacy of anti-VEGF therapy to improve the therapeutic outcome of nAMD.

作者程子芳王海燕王雨生

机构地区第四军医大学西京医院眼科全军眼科研究所

出处《中华眼底病杂志》 CAS CSCD 北大核心 2017年第2期199-202,共4页 Chinese Journal of Ocular Fundus Diseases

基金国家自然科学基金（81200708、81300770）

关键词黄斑变性/药物疗法血管生成抑制剂/治疗应用抗体单克隆/治疗应用综述 Age-related macular degeneration/drug therapy Choroidal neovascularization/drug therapy Angiogenesis inhibitors/therapeutic use Review

分类号 R774.5 [医药卫生—眼科]

作者简介通信作者：王雨生，Email：wangys003@126．com

引文网络
相关文献

参考文献2

1白玉婧,黎晓新.新生血管性老年性黄斑变性药物治疗面临的挑战与未来的发展趋势[J].中华眼底病杂志,2016,32(1):3-7. 被引量：23
2戴虹,卢颖毅.全面评估抗血管内皮生长因子药物治疗新生血管性老年性黄斑变性的影响因素，努力提高治疗效果的综合收益[J].中华眼底病杂志,2016,32(1):8-11. 被引量：17

二级参考文献59

1Ferris FL 3rd,Wilkinson CP,Bird A,et al.Clinical classification of age-related macular degeneration[J]. Ophthalmology,2013,120(4):844-851.DOI:10.1016/j. ophtha.2012.10.036.
2Das A,McGuire PG.Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition[J],Prog Retin Eye Res,2003,22(6):721-748.
3Zarbin MA.Current concepts in the pathogenesis of age-related macular degeneration[J].Arch Ophthalmol,2004,122(4):598-614.DOI:10.1001/archopht.122.4.598.
4Rosenfeld PJ,Brown DM,Heier JS,et al.Ranibizumab for neovascular age-related macular degeneration[J].N Engl J Med,2006,355(14):1419-1431.DOI:10.1056/ NEJMoa054481.
5Brown DM,Kaiser PK,Michels M,et al.Ranibizumab versus verteporfin for neovascular age-related macular degeneration[Jj. N Engl J Med,2006,355(14):1432-1444,DOI;10.1056/ NEJMoa062655.
6Martin DF,Maguire MG,Ying GS,et al.Ranibizumab and bevacizumab for neovascular age-related macular degeneration [J].N Engl J Med,2011,364(20):1897-1908.DOI:10.1056/ NEJMoall02673.
7Clinical Trials and Evaluation Unit(CTEU)Bristol.The IVAN Trial[EB/OL].C 2012-03-12)[2015-12-23].http://cteu.bris. ac.uk/trials/ivan.
8Macular Photocoagulation Study Group.Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration[J].Arch Ophthalmol,1993,111:1200-1209.
9Regillio CD,Brown DM,Abraham P,et al.Randomized double-masked,sham-controlled trial of ranibizumab for neovascular age-related macular degeneration:PIER Study year I[J].Am J Ophthalmol,2008,145(2):239-248.DOI:10.1016/j.ajo.2007.10.004.
10Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial[J].Arch Ophthalmol,1982,100(6):912-918.